KLRS
Kalaris Therapeutics Inc
1W: -23.5%
1M: -39.6%
3M: -36.4%
YTD: -20.1%
1Y: -42.2%
$6.57
-0.24 (-3.52%)
After Hours: $6.50 (-0.07, -1.07%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$122.9M
52W Range2.14-12.5
Volume57,896
Avg Volume68,864
Beta-0.14
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOAndrew Oxtoby
Employees14
SectorHealthcare
IndustryBiotechnology
IPO Date2020-07-30
Websitekalaristx.com
139 Main Street, Suite 500
Cambridge, MA 02142
US
Cambridge, MA 02142
US
About Kalaris Therapeutics Inc
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
Latest News
Kalaris Therapeutics, Inc. GAAP EPS of -$2.85
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Average Recommendation of “Moderate Buy” from Analysts
Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Oxtoby Andrew | A-Award | 222,000 | $6.81 | 2026-03-19 |
| Gall Matthew | A-Award | 95,000 | $6.81 | 2026-03-19 |
| Feinsod Matthew | A-Award | 135,000 | $6.81 | 2026-03-19 |
| AKKARAJU SRINIVAS | A-Award | 1,500,000 | $10.00 | 2025-12-22 |
| AKKARAJU SRINIVAS | P-Purchase | 479,847 | $10.42 | 2025-12-18 |